AbbVie preps a challenge to a rival migraine drug from Biohaven, spelling out an upbeat set of PhIII data

Phase III advance trial data for AbbVie’s migraine prevention drug atogepant look good — but are the results good enough to rival Biohaven’s two-in-one treatment and prevention drug, rimegepant, sold as Nurtec?

AbbVie picked up atogepant from Allergan in a $63 billion buyout last year. It also claimed the Botox franchise and $16 billion in annual revenue.